For more than a quarter of a century, Mr. Rein has focused on patent litigation, strategic counseling and patent-related due diligence. Many of his litigation matters have concerned well-known pharmaceutical products such as CARDIZEM, CLARITIN, DITROPAN XL, ELOXATIN, LIPITOR, LOVAZA, MONOPRIL, REBETOL, PRISTIQ, SELDANE, WELLBUTRIN XL and ZANTAC. See, e.g., Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., 217 F.Supp.3d 782 (D. Del. 2016) (Trial victory relating to a generic version of NASONEX based on Mr. Rein’s examination of the parties’ expert witnesses including Merck’s expert who used one of the world’s most powerful X-ray diffraction facilities, the synchrotron at Argonne National Laboratory, in an unsuccessful attempt to prove infringement).
Prior to joining Goodwin in 2001 to help start its IP law practice in New York, Mr. Rein was a partner at a well-known IP law firm. Earlier in his career, he clerked at the U.S. District Court for the Central District of California (located in Los Angeles). He previously served on the Patents Committee of the Association of the Bar of the City of New York and is currently involved in the Israel Practice committee of the American Intellectual Property Law Association (AIPLA) and the Tech Division committee of UJA. Mr. Rein has also partnered with The Legal Aid Society with respect to litigation relating to Title VII of the Civil Rights Act of 1964.